1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Aldeyra received minutes from a June 10, 2026 Type A meeting with the FDA about potential resubmission of the New Drug Application for reproxalap, a treatment for dry eye disease. The company has asked the FDA for a clarification of the minutes and plans to request a Type D meeting to discuss resubmission, which is expected by the end of the third quarter of 2026.
Type A meeting with the FDA held June 10, 2026; minutes received July 14, 2026
Clarification of the minutes requested from the FDA on July 15, 2026
Type D meeting on NDA resubmission expected by end of third quarter 2026
Marwynn Holdings, Inc. disclosed that Nasdaq notified it on July 10, 2026, that it had regained compliance with the $1.00 minimum bid price requirement for continued listing. The company had received a deficiency notice on January 29, 2026, and had until July 28, 2026 to regain compliance. The filing shows the stock closed at or above $1.00 for 10 consecutive business days, which removes the risk of delisting on this issue.
Nasdaq deficiency notice received January 29, 2026, for bid price below $1.00 for 30 consecutive business days
Nasdaq letter dated July 10, 2026, confirmed compliance with Listing Rule 5550(a)(2)
Closing bid price at or above $1.00 for 10 consecutive business days, June 25 to July 9, 2026
Axsome Therapeutics said the FDA accepted its New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 is not approved by the FDA, and the filing contains no financial results.
FDA accepted the New Drug Application for AXS-12 (reboxetine) for cataplexy in narcolepsy for filing
PDUFA target action date set for May 1, 2027
FDA does not currently plan to hold an advisory committee meeting
AXS-12 has FDA Orphan Drug Designation for the treatment of narcolepsy
SemiLEDs disclosed that Nasdaq had notified it on January 30, 2026 that its stockholders' equity fell below the $2.5 million minimum, and that Nasdaq accepted its compliance plan with an extension of up to 180 calendar days. The company now believes it has regained compliance, based on stockholders' equity of $3.1 million as of May 31, 2026, but Nasdaq will keep monitoring and could start delisting if the next periodic report does not show compliance.
Nasdaq notice dated January 30, 2026 cited stockholders' equity below the $2.5 million minimum under Listing Rule 5550(b)(1)
Nasdaq accepted the company's plan and granted an extension of up to 180 calendar days from January 30, 2026
Total stockholders' equity was $3.1 million as of May 31, 2026, per the Form 10-Q
Company believes it has regained compliance; Nasdaq will monitor compliance in the next periodic report
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.